These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 4734384)

  • 1. Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).
    Hunsicker LG; Ruddy S; Austen KF
    J Immunol; 1973 Jan; 110(1):128-38. PubMed ID: 4734384
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum proteins involved in decay and regeneration of cobra venom factor-dependent complement activation.
    Fearon DT; Austen KF; Ruddy S
    J Immunol; 1973 Dec; 111(6):1730-6. PubMed ID: 4796101
    [No Abstract]   [Full Text] [Related]  

  • 3. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
    Koethe SM; Austen KF; Gigli I
    J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
    [No Abstract]   [Full Text] [Related]  

  • 4. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    Ballow M; Cochrane CG
    J Immunol; 1969 Nov; 103(5):944-52. PubMed ID: 4981797
    [No Abstract]   [Full Text] [Related]  

  • 5. Complement-dependent B-cell activation by cobra venom factor and other mitogens?
    Dukor P; Schumann G; Gisler RH; Dierich M; König W; Hadding U; Bitter-Suermann D
    J Exp Med; 1974 Feb; 139(2):337-54. PubMed ID: 4589989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemolysis by the complement of tanned erythrocytes coated with cobra venom factor: a sensitive method to detect the alternative complement pathway activity of serum.
    Okada H; Tanaka H
    J Immunol Methods; 1981; 46(1):85-95. PubMed ID: 6793665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.
    Vogt W; Dieminger L; Lynen R; Schmidt G
    Hoppe Seylers Z Physiol Chem; 1974 Feb; 355(2):171-83. PubMed ID: 4215726
    [No Abstract]   [Full Text] [Related]  

  • 8. Activation of the alternative (properdin) pathway by divalent cations.
    Lew FT; Yukiyama Y; Waks HS; Osler AG
    J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bypass-activation of the complement system starting with C3. I. Generation and function of an enzyme from a factor of guinea-pig serum and cobra venom.
    Bitter-Suermann D; Dierich M; König W; Hadding U
    Immunology; 1972 Sep; 23(3):267-81. PubMed ID: 4214761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo abrogation of serum C3 and C5 by administration of cobra venom factor and heterologous anti-C3.
    Drake WP; Pokorney DR; Mardiney MR
    J Immunol Methods; 1974 Dec; 6(1-2):61-72. PubMed ID: 4215835
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).
    Alper CA; Balavitch D
    Science; 1976 Mar; 191(4233):1275-6. PubMed ID: 56780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative complement pathway activity in sera from patients with sickle cell disease.
    Koethe SM; Casper JT; Rodey GE
    Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.
    Hunsicker LG; Ruddy S; Carpenter CB; Schur PH; Merrill JP; Müller-Eberhard HJ; Austen KF
    N Engl J Med; 1972 Oct; 287(17):835-40. PubMed ID: 4627271
    [No Abstract]   [Full Text] [Related]  

  • 15. Participation of an early component of complement and Hageman factor in C3 destruction by zymosan.
    Gigli I; Koethe S; Austen KF
    Clin Immunol Immunopathol; 1975 Jul; 4(2):189-98. PubMed ID: 1170051
    [No Abstract]   [Full Text] [Related]  

  • 16. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.
    Müller-Eberhard HJ; Fjellström KE
    J Immunol; 1971 Dec; 107(6):1666-72. PubMed ID: 5120401
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune hemolysis and a basic peptide from cobra venom.
    Okada H; Campbell W
    J Immunol; 1974 Nov; 113(5):1647-9. PubMed ID: 4472944
    [No Abstract]   [Full Text] [Related]  

  • 18. Physicochemical characterization of the fifth (C5), sixth (C6), seventh (C7), eighth (C8) and ninth (C9) component of guinea pig complement.
    König W; Bitter-Suermann D; Dierich M; Hadding U
    Eur J Immunol; 1971 Nov; 1(5):372-6. PubMed ID: 5157761
    [No Abstract]   [Full Text] [Related]  

  • 19. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The C3-activator system: an alternate pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    J Exp Med; 1971 Sep; 134(3 Pt 2):90s-108s. PubMed ID: 4105810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.